PF-00835231 and Hepatitis-C--Chronic

PF-00835231 has been researched along with Hepatitis-C--Chronic* in 1 studies

Other Studies

1 other study(ies) available for PF-00835231 and Hepatitis-C--Chronic

Article	Year
Discovery and Crystallographic Studies of Trisubstituted Piperazine Derivatives as Non-Covalent SARS-CoV-2 Main Protease Inhibitors with High Target Specificity and Low Toxicity. Journal of medicinal chemistry, 2022, 10-13, Volume: 65, Issue:19 The continuous spread of SARS-CoV-2 calls for more direct-acting antiviral agents to combat the highly infectious variants. The main protease (M Topics: Antiviral Agents; Caspase 3; Cathepsins; Coronavirus 3C Proteases; COVID-19; Cysteine Endopeptidases; Hepatitis C, Chronic; Humans; Molecular Docking Simulation; Orotic Acid; Piperazines; Protease Inhibitors; SARS-CoV-2	2022

Article

Year

Discovery and Crystallographic Studies of Trisubstituted Piperazine Derivatives as Non-Covalent SARS-CoV-2 Main Protease Inhibitors with High Target Specificity and Low Toxicity.

Journal of medicinal chemistry, 2022, 10-13, Volume: 65, Issue:19

The continuous spread of SARS-CoV-2 calls for more direct-acting antiviral agents to combat the highly infectious variants. The main protease (M

Topics: Antiviral Agents; Caspase 3; Cathepsins; Coronavirus 3C Proteases; COVID-19; Cysteine Endopeptidases; Hepatitis C, Chronic; Humans; Molecular Docking Simulation; Orotic Acid; Piperazines; Protease Inhibitors; SARS-CoV-2

2022